Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001628280-25-002705
Filing Date
2025-01-27
Accepted
2025-01-27 18:15:12
Documents
1
Period of Report
2025-01-23

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1738019705.html 4  
1 FORM 4 wk-form4_1738019705.xml 4 5621
  Complete submission text file 0001628280-25-002705.txt   7227
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Issuer) CIK: 0001501697 (see all company filings)

EIN.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O MILLENDO THERAPEUTICS, INC. 110 MILLER AVENUE, SUITE 100 ANN ARBOR MI 48104
Business Address
Arbet-Engels Christophe (Reporting) CIK: 0001802615 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38295 | Film No.: 25560420